<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The cellular oncotic pathways affected by flaxseed and its bioactive components include a modulation of estrogen metabolism [
 <xref rid="B36-nutrients-11-01171" ref-type="bibr" class="xref">36</xref>], an inhibition of cellular proliferation, angiogenesis, metastasis and inflammation, as well as a stimulation of apoptosis within the tumour [
 <xref rid="B36-nutrients-11-01171" ref-type="bibr" class="xref">36</xref>,
 <xref rid="B38-nutrients-11-01171" ref-type="bibr" class="xref">38</xref>,
 <xref rid="B41-nutrients-11-01171" ref-type="bibr" class="xref">41</xref>,
 <xref rid="B42-nutrients-11-01171" ref-type="bibr" class="xref">42</xref>,
 <xref rid="B43-nutrients-11-01171" ref-type="bibr" class="xref">43</xref>,
 <xref rid="B45-nutrients-11-01171" ref-type="bibr" class="xref">45</xref>,
 <xref rid="B46-nutrients-11-01171" ref-type="bibr" class="xref">46</xref>]. The molecular targets for the anti-tumour actions of flaxseed and its bioactive components include a suppression of the phosphorylation of p-AKT, p-ERK and p-JNK kinases (resulting in a general slowing of the MAPK pathways) [
 <xref rid="B43-nutrients-11-01171" ref-type="bibr" class="xref">43</xref>,
 <xref rid="B46-nutrients-11-01171" ref-type="bibr" class="xref">46</xref>], inhibition of CDK4 [
 <xref rid="B45-nutrients-11-01171" ref-type="bibr" class="xref">45</xref>], down regulation of multiple miRNAs [
 <xref rid="B44-nutrients-11-01171" ref-type="bibr" class="xref">44</xref>], decreased expression of mRNAs for Bcl2, cell cycle proteins, ERalpha and beta and epidermal and insulin-like growth factor receptors [
 <xref rid="B46-nutrients-11-01171" ref-type="bibr" class="xref">46</xref>].
</p>
